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RESEARCH ARTICLE

A prospective, multi-center, randomized comparison of iron
isomaltoside 1000 versus iron sucrose in patients with iron
deficiency anemia; the FERWON-IDA trial
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Abstract
Iron deficiency anemia (IDA) is prevalent, and intravenous iron, especially if given in a
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single dose, may result in better adherence compared with oral iron. The present trial
(FERWON-IDA) is part of the FERWON program with iron isomaltoside 1000/ferric
derisomaltose (IIM), evaluating safety and efficacy of high dose IIM in IDA patients of
mixed etiologies. This was a randomized, open-label, comparative, multi-center trial
conducted in the USA. The IDA patients were randomized 2:1 to a single dose of
1000 mg IIM, or iron sucrose (IS) administered as 200 mg intravenous injections, up

5

Department of Clinical and Non-clinical
Research, Pharmacosmos A/S, Holbaek,
Denmark
6

Department of Medicine, Division of
Hematology Oncology, UCLA School of
Medicine, Los Angeles, California

to five times. The co-primary endpoints were adjudicated serious or severe hypersensitivity reactions, and change in hemoglobin from baseline to week eight. A total of
1512 patients were enrolled. The frequency of patients with serious or severe hypersensitivity reactions was 0.3% (95% confidence interval: 0.06;0.88) vs 0.4%
(0.05;1.45) in the IIM and IS group, respectively. The co-primary safety objective was

Correspondence
Michael Auerbach, Clinical Professor of
Medicine, Georgetown University School of
Medicine, Washington, DC.
Email: mauerbachmd@abhemonc.com

met, and no risk difference was observed between groups. The co-primary efficacy
endpoint of non-inferiority in hemoglobin change was met, and IIM led to a significantly more rapid hematological response in the first two weeks. The frequency of
cardiovascular events was 0.8% and 1.2% in the IIM and IS group, respectively
(P = .570). The frequency of hypophosphatemia was low in both groups. Iron isomaltoside administered as 1000 mg resulted in a more rapid and more pronounced
hematological response, compared with IS, which required multiple visits. The safety
profile was similar with a low frequency of hypersensitivity reactions and cardiovascular events.

and hypersensitivity reactions.4 The European Medicines Agency has

1 | I N T RO D UC T I O N

officially raised concerns about rare hypersensitivity reactions following
Intravenous (IV) iron is commonly used for the treatment of iron
1-3

deficiency anemia (IDA) as an alternative to oral iron.

IV iron administration. Published evidence suggests that the overwhelm-

Historically,

ing majority of acute infusion reactions are mild and are not due to hyper-

IV iron has been associated with a number of safety concerns, includ-

sensitivity but rather complement activation.5,6 These minor reactions

ing the potential for inducing oxidative stress, cardiovascular toxicity,

usually consisting of pressure in chest or back or flushing are self-limited
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and do not require intervention.7,8 Unfortunately due to fears of anaphy-

run-in period, two telephone visits to assess compliance and tolerance,

laxis, inappropriate intervention with vasopressors and antihistamines con-

and one visit to assess compliance, tolerance, and response) were sched-

vert minor reactions to serious adverse events, ostensibly attributed to the

uled. Those randomized to IS attended two additional visits, if deemed

IV iron. Clinical trials evaluating iron safety are often limited by small num-

necessary to achieve the cumulative dose of IS required.

bers not statistically powered to detect small differences in rare hypersensi-

The protocol and amendments were approved by the relevant

tivity reactions.9 The FIRM trial included 1997 IDA patients and provided a

Institutional Review Boards and conducted in accordance with good

direct comparative assessment of incidences of hypersensitivity reactions

clinical practice and the Declaration of Helsinki of 1975, as revised in

and hypotension associated with ferumoxytol and ferric carboxymaltose

2008. The trial was registered with ClinicalTrials.gov (NCT02940886).

(FCM), reporting incidences of moderate-to-severe hypersensitivity reac-

Written informed consent was obtained from all participants.

tions, including anaphylaxis, or moderate-to-severe hypotension of 0.6%
and 0.7% in the ferumoxytol and FCM groups, respectively.10

2.2 | Participants

IV iron has been shown to be beneficial in heart failure with guidelines now recommending IV iron to this population.11 However, some

The trial was conducted at 114 sites in the USA. Patients were ≥18 years

IV iron formulations bind the elemental iron less tightly with subse-

with IDA of different etiologies, and had intolerance or lack of response

quent higher amounts of labile free iron,12 which is toxic and causes

to oral iron or screening hemoglobin (Hb) measurement sufficiently low

playing a vital role in the mecha-

to require rapid repletion of iron stores. Patients with Hb ≤11 g/dL,

nisms behind cardiovascular diseases.14 Thus, IV iron formulations with

transferrin saturation (TSAT) <20%, and s-ferritin <100 ng/mL, were

a carbohydrate binding the iron more tightly resulting in slower release,

allowed to participate in the trial, after having signed the informed con-

allow much higher dosing in a significantly shorter period of time miti-

sent form. Inclusion and exclusion criteria are shown in Table S1.

13

oxidative stress and cell damage,

gating the preponderance of side effects due to free/labile iron.
The FERWON program with iron isomaltoside 1000/ferric
derisomaltose (IIM) was initiated in order to evaluate the safety and efficacy of IIM and iron sucrose (IS) with a focus on serious or severe hypersensitivity reactions. Other IV iron products available in the US and EU
are characterized by a structure with an iron core surrounded by a carbohydrate shell. By contrast, IIM has a unique defined matrix structure with
alternating iron molecules and linear isomaltoside 1000 oligomers. The
resulting matrix contains about 10 iron molecules per isomaltoside oligosaccharide in a strong and stably bound structure that enables a controlled and slow release of bioavailable iron to iron binding proteins with
little risk of free iron toxicity.12 As a result, it can be administered in high

2.3 | Interventions
Randomization was 2:1 to two groups. Onewas IIM (Monofer/Monoferric,
Pharmacosmos A/S, Holbaek, Denmark) administered at baseline, as a
single dose of 1000 mg infused over 20 minutes. The other was iron
sucrose (Venofer, American Regent, Shirley, New York, USA) administered as 200 mg IV injections according to label and repeated up to five
times (a cumulative dose of 1000 mg was recommended). During the
trial, other iron supplementation than the investigational drug, blood
transfusion, and erythropoiesis stimulating agents were prohibited.

2.4 | Objectives and endpoints

doses and previous published clinical trials demonstrate good safety and
efficacy of IIM in various populations with different comparators.15-27

The trial was designed with the objectives to evaluate and compare

The FERWON program consists of two trials including 3050 IDA

safety and efficacy of IIM to IS in patients with IDA, when oral iron

patients with either different clinical diagnoses (FERWON-IDA trial) or

formulations were ineffective or could not be used, or where there

chronic kidney disease (FERWON-NEPHRO trial). Herein we present the

was a clinical need to deliver iron rapidly.

results of the FERWON-IDA trial. The aim was to evaluate the safety
and efficacy of IIM and iron sucrose (IS) in a broad population with IDA.

The co-primary endpoints were number with adjudicated serious or
severe hypersensitivity reactions, starting on or after the first dose of
treatment, and change in Hb from baseline to week eight. The second-

2 | METHODS
2.1 | Trial design

ary safety endpoints included adjudicated composite cardiovascular
adverse events (AEs), starting on or after the first dose of randomized
treatment, and the incidence of hypophosphatemia (s-phosphate
<2.0 mg/dL), which was measured at all site visits. The secondary effi-

This was a prospective, comparative, open-label, randomized, multi-

cacy endpoints included Hb increase of ≥2 g/dL and s-ferritin level of

center trial. For each individual, duration of the trial was approxi-

≥100 ng/mL and TSAT of 20% to 50%. Also included were changes in

mately 10 to 15 weeks. All attended at least six visits (a screening

Hb, s-ferritin, TSAT, and fatigue symptoms measured by the Functional

visit, a baseline visit including investigational product administration,

Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale.

three assessment visits at week one, two, and four, and a final visit at

Adjudication of serious or severe hypersensitivity reaction and com-

week eight). If no documented intolerance of oral iron was present for

posite cardiovascular AEs was performed in a blinded fashion by an inde-

at least one month, within the last nine months prior to enrolment, a

pendent Clinical Endpoint Adjudication Committee. The hypersensitivity

run-in period with oral iron for up to one month to document intoler-

terms were defined by a standardized set of Medical Dictionary for Reg-

ance or lack of response to oral iron was required. One to four addi-

ulatory Activities (MedDRA) terms, which are listed in Table S2. The

tional visits during the run-in period (one telephone visit to initiate the

terms were based on discussions with FDA.
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2.5 | Sample size
The significance level was set to 5%. With N = 1000 in the IIM treatment
group, the power was 88% for demonstrating that the upper boundary of
the 95% confidence interval (CI) of the incidence of treatment emergent

Randomization was stratified according to the type of underlying disease (gastroenterology, gynecology, oncology, and “other”), and baseline cardiovascular risk (history of myocardial infarction, stroke, or
congestive heart failure). The block size was six.

for serious or severe hypersensitivity reactions, was less than 3%. The incidence rate of 3% was based on the incidences reported for the same endpoint on FCM and IS28 The upper boundary of the 95% CI for the
incidence of serious or severe hypersensitivity reaction, should be less
than 3% (2 × 1.5%) in the IIM treatment group, in order to meet the coprimary safety objective. With N = 500 in the IS group, assuming no difference between the treatment groups, and assuming a common SD (SD) of
1.5 g/dL, the power was 100% for demonstrating non-inferiority of the
change in Hb from baseline to week eight, using a non-inferiority margin
of −0.5 g/dL. This yielded a total power of 88% for demonstrating both
co-primary endpoints.

2.6 | Randomization

2.7 | Data analysis sets
The following data sets were used in the analyses (Figure 1).
The intention to treat (ITT) analysis set (N = 1512) included all randomized. This was used for evaluating efficacy.
The safety analysis set (N = 1483) included all randomized who
received at least one dose of the trial drug. This was used for evaluating
safety.
The full analysis set (FAS; N = 1457) included all randomized
patients who received at least one dose of the trial drug, and had at
least one post-baseline Hb assessment. This was used for a sensitivity
analysis of the co-primary efficacy endpoint.

A stratified block randomization methodology was used in the trial,

The per protocol (PP) analysis set (N = 1338) included all in the

and randomization was a 2:1 ratio to receive IIM or IS, respectively.

FAS who did not have any major protocol deviations of clinical or

FIGURE 1

Patient disposition. IIM, iron isomaltoside 1000/ferric derisomaltose; IS, iron sucrose
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Baseline demographics and laboratory parameters are summarized
in Table 1. Overall baseline characteristics were comparable between
the treatment groups. Approximately 50% were gynecology patients

2.8 | Statistical analyses

and 26% were gastroenterology patients.

The co-primary safety endpoint, serious or severe hypersensitivity reaction, was summarized, and if the upper boundary of the 95% CI was <3%,
the safety objective was met. In addition, as supportive information, the
risk difference between IIM and IS was assessed by constructing a 95% CI

3.2 | Exposure to iron
A total of 989 patients received IIM, and 494 patients received
IS. One infusion in the IIM group, and one to five infusions in the IS

of the risk difference. The overall incidence of composite cardiovascular
AEs, and frequency of patients with adverse drug reactions (ADRs), were
compared between the treatment groups by a Fisher's exact test.
The co-primary efficacy endpoint, change in Hb from baseline to

T A B L E 1 Summary of baseline demographics, hemoglobin,
s-ferritin, transferrin saturation, and s-iron (intention to treat
analysis set)
IIM

week eight, was tested for non-inferiority by using a mixed model for
repeated measurements (MMRM) with a restricted maximum likeli-

IS

Age (years)

hood (REML)-based approach. The model included the fixed, categori-

N

1009

503

cal effects of treatment, week, treatment-by-week interaction, strata,

Mean (SD)

44.1 (14.8)

43.8 (14.4)

Min;max

18;91

18;91

Women

892 (88.4)

456 (90.7)

Men

117 (11.6)

47 (9.3)

504 (50.0)

264 (52.5)

and the continuous covariates of baseline Hb and baseline Hb-byweek interaction. Non-inferiority of IIM against IS could be claimed if
the lower boundary of the 95% CI was above −0.5 g/dL.
The secondary efficacy endpoints were tested for superiority. Incidence of Hb responders to each week (defined as an increase in Hb of at
least 2 g/dL from baseline to the week in question) was analyzed using a
repeated measures logistic regression model with treatment, visit, strata,

Gender (N [%])

Race (N [%])
White

and treatment by visit interaction as fixed effects and baseline value as

Asian

covariate.

Black or African American

Time to Hb response was estimated using the Kaplan-Meier
method. The hypothesis of no treatment difference was assessed by a
two-sided log-rank test.
The incidence of patients who achieved a s-ferritin level of
≥100 ng/mL and a TSAT of 20-50% at any time were analyzed using a
logistic regression model with treatment and strata as fixed effects.

8 (0.8)

4 (0.8)

484 (48.0)

223 (44.3)

American Indian or
Alaska Native

4 (0.4)

1 (0.2)

Native Hawaiian or other
Pacific Islander

1 (0.1)

2 (0.4)

Other

8 (0.8)

9 (1.8)

Ethnicity (N [%])

The MMRM, with treatment, week, treatment-by-week interaction,

Hispanic or Latino

387 (38.4)

205 (40.8)

and strata as factors and baseline value and baseline value-by-week

Not Hispanic or Latino

622 (61.6)

298 (59.2)

N

1009

503

Mean (SD)

9.25 (1.28)

9.17 (1.27)

Min;Max

4.0;13.5

5.2;13.8

N

1009

503

Mean (SD)

14.4 (42.6)

11.9 (37.6)

(Min;max)

1;729

1;715

N

1009

503

Mean (SD)

7.43 (10.93)

6.69 (7.44)

(Min;max)

1;176

1;84

interaction as covariates, was used to compare the average change in
Hb, s-ferritin, TSAT, and fatigue symptoms.
All tests were two-tailed and the significance level was 0.05. The
baseline characteristics and other safety data (including incidence of
hypophosphatemia) were displayed descriptively.
Patients and investigators were not blinded to trial medications during the trial. However, the hypersensitivity reactions and cardiovascular
AEs were evaluated centrally by a blinded independent adjudication
committee. Also, laboratory parameters were evaluated at a central laboratory, so it was not deemed necessary to have a blinded trial design.

3 | RESULTS
3.1 | Patients
A group of 3108 patients were screened of whom 1512 were randomized 2:1 to the IIM group (1009) or IS group (503). Of the 1512
enrolled, 1356 (90%) completed the trial. The details of patient disposition are summarized in Figure 1.

Hemoglobin (g/dL)

S-ferritin (ng/mL)

Transferrin saturation (%)

Note: Some patients had baseline hemoglobin, transferrin saturation, and
s-ferritin values that were increased above the inclusion screening values
(hemoglobin ≤11 g/dL, transferrin saturation < 20%, and s-ferritin
<100 ng/mL).
Abbreviations: %, percentage of patients; IIM, iron isomaltoside
1000/ferric derisomaltose; IS, iron sucrose; Max, maximum;
Min, minimum; N, number of patients; SD, standard deviation.
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group were administered, with the majority receiving five (80%; mean:

The hypophosphatemia events were transient, and in most cases

4.5 administrations, median: 5 administrations). The mean dose for

normalized at the end of the trial. For the majority, the lowest s-phos-

IIM and IS was 975 mg (SD: 145), and 905 mg (SD: 217), respectively.

phate values were reached at week one or two.
The incidence of severe hypophosphatemia (s-phosphate <1.0 mg/dL)
was 0.0% in both groups, as no patient had a s-phosphate level < 1.0 mg/dL

3.3 | Serious or severe hypersensitivity reactions co-primary safety endpoint

during the trial.

The safety analyses were conducted on the safety analysis set

3.6 | Adverse drug reactions and other safety data

(N = 1483).
A total of three serious or severe hypersensitivity reactions were
reported in 3/989 (0.3%; 95% CI: 0.06;0.88) patients in the IIM group,
and two serious or severe hypersensitivity reactions were reported in
2/494 (0.4%; 95% CI: 0.05;1.45) in the IS group. As the upper boundary

A total of 230 ADRs in 124 patients (12.5%) were reported in the IIM
group, and 138 ADRs in 63 patients (12.8%) were reported in the IS
group (P > .05). The most common ADR was nausea (20 events in
20 patients [2.0%] in the IIM group and 10 events in 8 patients [1.6%]
in the IS group). Rash (17 ADRs in 15 patients [1.5%]) and chest dis-

of the 95% CI was <3%, the co-primary safety endpoint was met. The

comfort (11 ADRs in 11 patients [1.1%]) were reported more fre-

risk difference between IIM and IS, with respect to adjudicated and con-

quently in the IIM group than in the IS group (0 ADR and 0 ADR,

firmed treatment emergent serious or severe hypersensitivity reactions

respectively). Dysgeusia (20 ADRs in 9 patients [1.8%]) and overdose

was estimated to −0.10% (95% CI: −0.91;.71). The difference between

(10 ADRs in 8 patients [1.6%]), were more common in the IS group

the two treatment groups was not statistically significant as the confi-

than in the IIM group (1 and 0 ADRs, respectively).

dence interval included zero. Narratives of the hypersensitivity reactions
are provided in Table S3.

One in the IIM group died three months after treatment with IIM in a
hospice. The event was reported as worsening of pre-existing cancer, in
a patient with underlying bile duct cancer, and was not related to the
trial drug.

3.4 | Composite cardiovascular adverse events
Eight composite cardiovascular AEs were reported in eight (0.8%) patients

3.7 | Change in hemoglobin

in the IIM group, and seven were reported in six (1.2%) in the IS group. The
incidence of composite cardiovascular AEs was, however, not statistically
significantly different between the two treatment groups (P > .05).

The co-primary efficacy analysis (change in Hb concentration from
baseline to week eight) was conducted on the ITT (N = 1512), FAS
(N = 1457), and PP analysis set (N = 1338), and the secondary efficacy
analyses were conducted on ITT.

3.5 | Hypophosphatemia

The increase in Hb concentration from baseline to weeks one and
two was statistically significantly greater for IIM compared with IS

The incidence of hypophosphatemia (s-phosphate <2.0 mg/dL) was low

(P < .0001). The increase from baseline to week four did not differ sta-

and similar in the two groups (3.9% in the IIM and 2.3% in the IS group).

tistically significantly between treatment groups (P = .109) (Figure 2).

F I G U R E 2 Hemoglobin, s-ferritin, and transferrin saturation over time by treatment group (intention to treat analysis set). Estimates
(mean and SE) from a mixed model with repeated measures with strata, treatment and time as factors, treatment*time and baseline value*time
interactions and baseline value as covariate. IMM, iron isomaltoside 1000/ferric derisomaltose; IS, iron sucrose. *P < .05, **P < .001, ***P < .001
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Analysis of change in hemoglobin (g/dL) from baseline to week eight

LS Mean [95% CI]

Difference IIM—IS
Estimate [95% CI]

Non-Inferiora

Superiority
test P-value

1009

2.49 [2.41;2.56]

0.00 [−0.13;0.13]

Yes

0.977

503

2.49 [2.38;2.59]

IIM

972

2.51 [2.43;2.58]

0.01 [−0.12;0.14]

Yes

0.834

IS

485

2.49 [2.39;2.60]

0.01 [−0.12;0.14]

Yes

0.871

Treatment

N

Intention to treat analysis set
IIM
IS
Full analysis set

Per protocol analysis set
IIM

901

2.58 [2.50;2.65]

IS

437

2.57 [2.46;2.68]

Abbreviations: CI, confidence interval; IIM, iron isomaltoside 1000/ferric dersisomaltose; IS, iron sucrose; LS Mean, Least square mean.
a
Non-inferiority could be claimed if the lower boundary of the 95% CI is above −0.5 g/dL.

A summary of the co-primary efficacy analysis is provided in Table 2.

increase in FACIT fatigue score from baseline to week one was signifi-

The change in Hb concentration from baseline to week eight was non-

cantly greater for IIM compared with IS (P = .042). The increase from

inferior for IIM compared to IS since the lower boundary of the 95% CI

baseline to weeks two and eight did not differ statistically significantly

for the treatment difference (IIM-IS) was above −0.5 g/dL. Superiority of

between treatment groups (Figure S1).

IIM vs IS could not be claimed since the 95% CI included zero. This was
confirmed in all three analysis sets (Table 2).
The proportion of responders (Hb increase of ≥2 g/dL from baseline) was statistically significantly higher in the IIM group, compared
to the IS group at weeks one and two, but not at weeks four or eight

4 | DISCUSSION
The objectives of this trial were to evaluate the safety with special
focus on the risk of hypersensitivity reactions, and efficacy of IV IIM,

(Table S4). The median time to Hb increase of ≥2 g/dL was 28 days in

in comparison to the widely used IS in a broad population with differ-

both the IIM and the IS groups (P = .088).

ent IDA etiologies. Iron sucrose was chosen as comparator in the trial,
as iron sucrose has consistently shown a low risk of hypersensitivity

3.8 | Change in s-ferritin and transferrin saturation

in clinical trials.29 The IDA etiology was in approximately 50% of cases
a gynecological disorder, and in 26% a gastroenterological disorder.

The proportion with s-ferritin ≥100 ng/mL and TSAT of 20% to 50%

Here, IDA was confirmed in all based on low values of Hb, TSAT,

at any time from weeks one to eight was statistically significantly

and s-ferritin at screening (Hb ≤11 g/dL, TSAT <20%, and s-ferritin

higher in the IIM group compared with the IS group (70% vs 34%,

<100 ng/mL). The mean cumulative dose was 975 mg (SD: 145) and

P < .0001).

905 mg (SD: 217) for IIM and IS, respectively. The cumulative doses

The increase in s-ferritin from baseline to weeks one and two was

reflect the difference in dosing opportunities between the two IV iron

statistically significantly greater for IIM compared with IS (s-ferritin:

products, where IIM allows administration of the full iron dose in one

P < .0001 at both weeks), while the increase from baseline to weeks

visit, whereas IS requires multiple visits to reach the same dose level.

four and eight did not differ statistically significantly between treat-

All except one received the full IIM dose, whereas only 80% received

ment groups (Figure 2).

the recommended IS dose.

The increase in TSAT from baseline to weeks one, two, and four

Three serious or severe hypersensitivity reactions in three (0.3%)

was statistically significantly greater for IIM compared with IS

patients were positively adjudicated in the IIM group, and two reactions

(P < .0001, P = .0001, and P = .016), while the increase from baseline

in two (0.4%) patients in the IS group. The 95% CI for the percentage

to week eight did not differ statistically significantly between treat-

reporting serious or severe hypersensitivity reactions in the IIM treat-

ment groups (Figure 2).

ment group was 0.06;0.88. As the upper boundary was <3%, the coprimary safety objective was met, and no risk difference to IS was

3.9 | Change in fatigue symptoms

observed. The frequencies of serious or severe hypersensitivity reac-

At baseline, more than half had severe fatigue (a FACIT fatigue

One explanation for this difference could be that the hypersensitivity

score <30 indicates severe fatigue) as indicated by a median FACIT

reactions reported in the review were not adjudicated and confirmed by

fatigue score of 24.0 in both treatment groups. The mean FACIT fatigue

an independent Clinical Endpoint Adjudication Committee, as in the pre-

score increased from baseline to week eight in both treatment groups

sent trial. In the FIRM trial, where moderate-to severe hypersensitivity

(IIM group: from 25.72 to 39.98; IS group: from 24.63 to 39.93). The

reactions, including anaphylaxis and hypotension, were assessed for

tions are lower than those published in a previous review of IV irons.30
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ferumoxytol and FCM, the frequencies were 0.6% and 0.7%, respectively.10 These reactions were also adjudicated by a blinded and independent Clinical Event Committee, however, the terms used for
defining a hypersensitivity event were different compared to our trial.
When comparing IIM with IS, there was no statistically significant
difference in the number with composite cardiovascular AEs (0.8% vs
1.2%) in this relative low risk population. A pre-specified pooled analy-
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quency of hypophosphatemia in different populations.

Non-inferiority was claimed for change in Hb from baseline to
week eight for IIM compared with IS, and treatment with IIM led to
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a higher increase in Hb at weeks one and two. This was supported
by the proportion of responders (Hb increase of ≥2 g/dL from baseline), which was statistically significantly higher in the IIM group
compared to the IS group at weeks one and two. The faster
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response was also shown for s-ferritin, and TSAT, and it is likely
due to the higher doses of IIM given within a shorter time period.
The faster efficacy response observed with IIM is consistent with a
previously reported trial performed with IIM and IS in an IDA
population.27
Both IIM and IS led to an increase in FACIT fatigue score with a
significant difference at week one in favor of iron isomaltoside. Thus,
treatment of IDA with IIM may not only lead to a correction of the
hematology parameters but may also increase QoL by decreasing
symptoms such as fatigue faster since IIM has a shorter treatment
period to reach the clinically required iron dose. In a sub-analysis of
women suffering from severe fatigue after postpartum hemorrhage, a
single dose of IIM was associated with a statistically significant and
clinically relevant reduction in aggregated physical fatigue within
12 weeks after delivery, when compared to current treatment practice with oral iron.32
In conclusion, IV IIM administration was well tolerated in a broad
population with IDA being intolerant or unresponsive to oral iron
therapy or being in need of iron rapidly. The number with serious or
severe hypersensitivity reactions was low for IIM with no risk difference to IS and hypophosphatemia was not a safety issue for IIM or
IS. Administration of a single dose of IV IIM provided a faster and
transiently greater Hb response within the first 2 weeks and was as
effective in ensuring an improvement in Hb concentration at 8 weeks
as IV IS given up to five doses over 2 weeks. This trial contributes to
the body of evidence demonstrating that IIM is safe and efficacious in
treatment of IDA in a single visit.

RE FE RE NCE S
1. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on
the diagnosis and management of iron deficiency and anaemia in
inflammatory bowel diseases. J Crohns Colitis. 2015;9:211-222.
2. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease.
2012. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012Anemia-Guideline-English.pdf. Accessed May 22, 2019.
3. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and
management of iron deficiency and anemia in inflammatory bowel
diseases. Inflamm Bowel Dis. 2007;13:1545-1553.
4. Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in
chronic kidney disease: conclusions from a “kidney disease: improving
global outcomes” (KDIGO) controversies conference. Kidney Int.
2016;89:28-39.
5. Macdougall IC, Vernon K. Complement activation-related pseudoallergy: a fresh look at hypersensitivity reactions to intravenous iron.
Am J Nephrol. 2017;45:60-62.
6. Hempel JC, Poppelaars F, Gaya da Costa M, et al. Distinct in vitro
complement activation by various intravenous iron preparations.
Am J Nephrol. 2017;45:49-59.
7. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions
to intravenous iron: guidance for risk minimization and management.
Haematologica. 2014;99:1671-1676.
8. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for
anaemia. Lancet. 2007;369:1502-1504.
9. Adkinson NF, Strauss WE, Bernard K, Kaper RF, Macdougall IC,
Krop JS. Comparative safety of intravenous ferumoxytol versus ferric
carboxymaltose for the treatment of iron deficiency anemia: rationale
and study design of a randomized double-blind study with a focus on
acute hypersensitivity reactions. J Blood Med. 2017;8:155-163.

1014

10. Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety
of intravenous ferumoxytol versus ferric carboxymaltose in iron
deficiency anemia: a randomized trial. Am J Hematol. 2018;
93:683-690.
11. Mordi IR, Tee A, Lang CC. Iron therapy in heart failure: ready for
primetime. Card Fail Rev. 2018;4:28-32.
12. Jahn MR, Andreasen HB, Futterer S, et al. A comparative study of the
physicochemical properties of iron isomaltoside 1000 (Monofer), a
new intravenous iron preparation and its clinical implications. Eur J
Pharm Biopharm. 2011;78:480-491.
13. Haase M, Bellomo R, Haase-Fielitz A. Novel biomarkers, oxidative
stress, and the role of labile iron toxicity in cardiopulmonary
bypass-associated acute kidney injury. J Am Coll Cardiol. 2010;55:
2024-2033.
14. Panth N, Paudel KR, Parajuli K. Reactive oxygen species: a key hallmark of cardiovascular disease. Adv Med. 2016;2016:9152732.
15. Hildebrandt PR, Bruun NE, Nielsen OW, et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A
pilot study. Transfus Altern Transfus Med. 2010;11:131-137.
16. Wikstrom B, Bhandari S, Barany P, et al. Iron isomaltoside 1000: a
new intravenous iron for treating iron deficiency in chronic kidney
disease. J Nephrol. 2011;24:589-596.
17. Reinisch W, Altorjay I, Zsigmond F, et al. A 1-year trial of repeated highdose intravenous iron isomaltoside 1000 to maintain stable hemoglobin
levels in inflammatory bowel disease. Scand J Gastroenterol. 2015;50:
1226-1233.
18. Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, noninferiority study of intravenous iron isomaltoside 1000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
Am J Gastroenterol. 2013;108:1877-1888.
19. Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute
coronary artery bypass graft, valve replacement or a combination
thereof: a randomized double-blind placebo-controlled clinical trial
(the PROTECT trial). Vox Sang. 2015;109:257-266.
20. Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of
iron isomaltoside 1000 (Monofer) compared with iron sucrose
(Venofer) as maintenance therapy in haemodialysis patients. Nephrol
Dial Transplant. 2015;30:1577-1589.
21. Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic
kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;
31:646-655.
22. Birgegard G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M.
A randomized, noninferiority trial of intravenous iron isomaltoside
versus oral iron sulfate in patients with nonmyeloid malignancies and
anemia receiving chemotherapy, the profound trial. Pharmacotherapy.
2016;36:402-414.
23. Dahlerup JF, Jacobsen BA, van der Woude J, Bark LA, Thomsen LL,
Lindgren S. High-dose fast infusion of parenteral iron isomaltoside is

AUERBACH ET AL.

24.

25.

26.

27.

28.

29.

30.
31.

32.

efficacious in inflammatory bowel disease patients with irondeficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 2016;51:1332-1338.
Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial. Vox Sang. 2017;
112:219-228.
Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot
study. Vox Sang. 2017;112:122-131.
Gybel-Brask M, Seeberg J, Thomsen LL, Johansson PI. Intravenous
iron isomaltoside improves hemoglobin concentration and iron stores
in female iron-deficient blood donors: a randomized double-blind
placebo-controlled clinical trial. Transfusion. 2018;58:974-981.
Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL,
Auerbach M. A randomized trial of iron isomaltoside versus iron sucrose
in patients with iron deficiency anemia. Am J Hematol. 2017;92:286-291.
Medical review of ferric carboxymaltose, application number
203565Orig1s000, Center for Drug Evaluation and Research, Food and
Drug Administration, July 21, 2013. Food and Drug Administration.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/
203565Orig1s000MedR.pdf. Accessed May 22, 2019
Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic
reactions associated with intravenous iron products. JAMA. 2015;
314:2062-2068.
Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney
disease. Curr Opin Nephrol Hypertens. 2016;25:529-535.
Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer)
in the management of patients with iron deficiency anemia. Int J Nephrol
Renovasc Dis. 2016;9:53-64.
Holm C, Thomsen LL, Langhoff-Roos J. Intravenous iron isomaltoside
treatment of women suffering from severe fatigue after postpartum
hemorrhage. J Matern Fetal Neonatal Med. 2019;32:2797-2804.

SUPPORTING INF ORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.

How to cite this article: Auerbach M, Henry D, Derman RJ,
Achebe MM, Thomsen LL, Glaspy J. A prospective, multicenter, randomized comparison of iron isomaltoside 1000
versus iron sucrose in patients with iron deficiency anemia;
the FERWON-IDA trial. Am J Hematol. 2019;94:1007–1014.
https://doi.org/10.1002/ajh.25564

